Aortic Valve Replacement With the Stentless Freedom SOLO Bioprosthesis: A Systematic Review

Laurens W. Wollersheim; Wilson W. Li; Berto J. Bouma; Alberto Repossini; Jan van der Meulen; Bas A. de Mol

doi:https://doi.org/10.1016/j.athoracsur.2015.06.048

Aortic Valve Replacement With the Stentless Freedom SOLO Bioprosthesis: A Systematic Review

Laurens W. Wollersheim, Wilson W. Li, Berto J. Bouma, Alberto Repossini, Jan van der Meulen, Bas A. de Mol

Research output: Contribution to journal › Review article › Academic › peer-review

12 Citations (Scopus)

Abstract

This systematic review examined the clinical and hemodynamic performance of the stentless Freedom SOLO (Sorin Group, Milan, Italy) aortic bioprosthesis. The occurrence of postoperative thrombocytopenia was also analyzed. The Freedom SOLO is safe to use in everyday practice, with short cross-clamp times, and postoperative pacemaker implantation is notably lower. Valvular gradients are low and remain stable during short-term follow-up. Thrombocytopenia is more severe than in other aortic prostheses; however, this is without clinical consequences. Within a few years, the 15-year follow-up of this bioprosthesis will be known, which will be key to evaluating its long-term durability

Original language	English
Pages (from-to)	1496-1504
Journal	Annals of Thoracic Surgery
Volume	100
Issue number	4
DOIs	https://doi.org/10.1016/j.athoracsur.2015.06.048
Publication status	Published - 2015

Access to Document

https://doi.org/10.1016/j.athoracsur.2015.06.048

Cite this

@article{964f66bf83e246da872354377ab7ccb9,

title = "Aortic Valve Replacement With the Stentless Freedom SOLO Bioprosthesis: A Systematic Review",

abstract = "This systematic review examined the clinical and hemodynamic performance of the stentless Freedom SOLO (Sorin Group, Milan, Italy) aortic bioprosthesis. The occurrence of postoperative thrombocytopenia was also analyzed. The Freedom SOLO is safe to use in everyday practice, with short cross-clamp times, and postoperative pacemaker implantation is notably lower. Valvular gradients are low and remain stable during short-term follow-up. Thrombocytopenia is more severe than in other aortic prostheses; however, this is without clinical consequences. Within a few years, the 15-year follow-up of this bioprosthesis will be known, which will be key to evaluating its long-term durability",

author = "Wollersheim, {Laurens W.} and Li, {Wilson W.} and Bouma, {Berto J.} and Alberto Repossini and {van der Meulen}, Jan and {de Mol}, {Bas A.}",

year = "2015",

doi = "https://doi.org/10.1016/j.athoracsur.2015.06.048",

language = "English",

volume = "100",

pages = "1496--1504",

journal = "Annals of Thoracic Surgery",

issn = "0003-4975",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Aortic Valve Replacement With the Stentless Freedom SOLO Bioprosthesis: A Systematic Review

AU - Wollersheim, Laurens W.

AU - Li, Wilson W.

AU - Bouma, Berto J.

AU - Repossini, Alberto

AU - van der Meulen, Jan

AU - de Mol, Bas A.

PY - 2015

Y1 - 2015

N2 - This systematic review examined the clinical and hemodynamic performance of the stentless Freedom SOLO (Sorin Group, Milan, Italy) aortic bioprosthesis. The occurrence of postoperative thrombocytopenia was also analyzed. The Freedom SOLO is safe to use in everyday practice, with short cross-clamp times, and postoperative pacemaker implantation is notably lower. Valvular gradients are low and remain stable during short-term follow-up. Thrombocytopenia is more severe than in other aortic prostheses; however, this is without clinical consequences. Within a few years, the 15-year follow-up of this bioprosthesis will be known, which will be key to evaluating its long-term durability

AB - This systematic review examined the clinical and hemodynamic performance of the stentless Freedom SOLO (Sorin Group, Milan, Italy) aortic bioprosthesis. The occurrence of postoperative thrombocytopenia was also analyzed. The Freedom SOLO is safe to use in everyday practice, with short cross-clamp times, and postoperative pacemaker implantation is notably lower. Valvular gradients are low and remain stable during short-term follow-up. Thrombocytopenia is more severe than in other aortic prostheses; however, this is without clinical consequences. Within a few years, the 15-year follow-up of this bioprosthesis will be known, which will be key to evaluating its long-term durability

U2 - https://doi.org/10.1016/j.athoracsur.2015.06.048

DO - https://doi.org/10.1016/j.athoracsur.2015.06.048

M3 - Review article

C2 - 26324106

SN - 0003-4975

VL - 100

SP - 1496

EP - 1504

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

IS - 4

ER -